About this trial
This study is a human challenge study to assess the minimum infective mosquito bite dose in a controlled human malaria Infection (via P. vivax sporozites) in healthy volunteers. The results will inform the development of a P. vivax mosquito-delivered CHMI trial platform, supporting safer and more accurate vaccine efficacy assessments. Conducting the trial in individuals genetically and immunologically similar to the target population will also enhance the relevance of findings to real-world endemic settings.
This study is funded by the UK Wellcome Trust. The grant reference number are Oxford/MORU: 212336/Z/18/Z and 212336/Z/18/A, and Mahidol University: 212336/A/18/Z and 212336/A/18/A.
Eligibility criteria
Qualifiers
Healthy adult aged 20 to 55 years with weight more than 50 kg.
No recent malaria infection.
Red blood cells positive for the Duffy antigen/chemokine receptor (DARC).
CYP2D6 alleles consistent with normal metaboliser status.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Mosquito bite (1 or 2 or 3)
Treatment groups
Sponsors and collaborators
University of Oxford
Lead sponsor
Mahidol University
Collaborator